Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Paediatric-onset autoimmune cytopenia: How can we reduce the long-term mortality?

British journal of haematology·2026

Same author

Ribosomal RNA processing impairments in a B cell immunodeficient patient with WDR75 variants.

Journal of human immunity·2026

Same author

Pharmacological stabilization of hypoxia-inducible factor 1-α dampens the interferon response and promotes glycolysis in Aicardi-Goutières syndrome.

Nature communications·2026

Same author

Author Correction: Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice.

Nature communications·2025

Same author

Inborn errors of immunity: Manifestation, treatment, and outcome-an ESID registry 1994-2024 report on 30,628 patients.

Journal of human immunity·2025

Same author

Lymphedema in patients with X-linked severe combined immunodeficiency.

The journal of allergy and clinical immunology. Global·2025

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Indications for hemopoietic stem cell transplantation.

Chaim M Roifman¹, Alain Fischer, Luigi D Notarangelo

¹Division of Immunology & Allergy, The Canadian Centre for Primary Immunodeficiency, The Jeffrey Modell Research Laboratory for the Diagnosis of Primary Immunodeficiency, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada. chaim.roifman@sickkids.ca

Immunology and Allergy Clinics of North America

|May 25, 2010

Summary

Hemopoietic stem cell transplantation is a vital treatment for primary immunodeficiencies, including severe combined immunodeficiency and autoimmune disorders. This review outlines established and potential indications, alongside limitations, for this life-saving therapy.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Area of Science:

Immunology
Hematology
Transplantation Medicine

Background:

Primary immunodeficiencies (PIDs) are a group of genetic disorders affecting the immune system.
Hemopoietic stem cell transplantation (HSCT) is a potentially curative treatment for severe PIDs.
Identifying appropriate candidates for HSCT is crucial for successful outcomes.

Purpose of the Study:

To provide a comprehensive list of indications for HSCT in patients with primary immunodeficiency.
To delineate both definite and possible criteria for considering HSCT.
To discuss associated causes and limitations of HSCT in this context.

Main Methods:

Systematic review of existing literature on HSCT for primary immunodeficiencies.
Compilation and categorization of established and potential indications.
Analysis of factors influencing HSCT outcomes and limitations.

Main Results:

Severe combined immunodeficiency (SCID) and other profound T cell defects are definite indications.
Autoimmune/autoinflammatory syndromes, innate immune defects, and hemophagocytic disorders are also included.
The list encompasses a range of conditions, acknowledging variability in evidence and patient-specific factors.

Conclusions:

HSCT is a critical therapeutic option for a spectrum of primary immunodeficiencies.
Careful patient selection based on defined indications and consideration of limitations are essential.
Further research may expand the scope of HSCT for complex immune disorders.